Verelan is a brand name for the extended-release form of verapamil hydrochloride. The core therapeutic domain of this medication involves conditions presenting with systemic or localized discomfort related to heightened physiological activity. The medication is commonly used to help with three primary conditions where symptoms may intensify temporarily.

Verelan is generally used for managing elevated high blood pressure (hypertension), certain types of chest pain (angina), and specific irregular heartbeats (arrhythmias). In clinical settings that involve acute or unstable symptom patterns, it helps to ease the overall symptom burden associated with systemic imbalance and supports the patient during difficult episodes. This supportive relief assists with maintaining functional stability when symptoms interfere with routine activities.

The medication may be part of symptomatic management across conditions characterized by periods of heightened symptoms. It also contributes to easing the overall symptom load.

“This helps improve day-to-day comfort during symptomatic periods.”

Quick Fact: Support for Physical Discomfort

Regulatory References

1. NIH MedlinePlus overview of Verapamil

Verelan (verapamil) is not appropriate for all patients and has specific, formal contraindications and population restrictions based on regulatory sources.

Contraindications

Verelan must not be used by patients with:

• Severe hypotension (low blood pressure).
• Cardiogenic shock or severe left ventricular dysfunction (severe heart failure).
• Second- or third-degree AV block or sick sinus syndrome (serious heart rhythm problems), unless a functioning artificial ventricular pacemaker is present.
• Atrial flutter or atrial fibrillation combined with an accessory bypass tract (e.g., Wolff-Parkinson-White or Lown-Ganong-Levine syndromes).

Special Consideration Populations

Population	Eligibility Status
Pediatric (Children)	Safety and effectiveness have not been established.
Hepatic Impairment (Liver)	Clearance is reduced; a significant dose reduction is typically required.
Renal Impairment (Kidney)	Use with caution; may require dose adjustment.
Pregnancy	Use is only if clearly needed and the potential benefit justifies the potential risk. (FDA Category C).
Lactation (Breastfeeding)	Discontinuation of nursing is recommended.

In summary, this medicine is strictly prohibited for those with specific serious, pre-existing heart conditions and is generally not recommended or requires special medical management for patients with significant organ impairment, during pregnancy, or in the pediatric age group.

Interactions with other medicines and products

The official regulatory profile for Verelan (Verapamil Hydrochloride) documents specific interaction patterns concerning co-administered medicines and substances.

---

Official Interaction Statements

Category	Documented Interaction Statement
Formal Contraindications	Co-administration with substances such as Colchicine, Flibanserin, and Lomitapide is formally contraindicated due to the documented risk of severe toxicity resulting from increased exposure. Intravenous beta-blockers are also contraindicated for administration in close proximity.
Pharmacokinetic Profile	Verapamil is documented as an inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. This leads to formally recognized increased plasma concentrations for numerous co-administered drugs, including Digoxin and certain statins (e.g., Simvastatin, Lovastatin). CYP3A4 inducers, such as Rifampicin, are documented to reduce Verapamil's exposure.
Pharmacodynamic Effects	The combination with oral beta-blockers or antiarrhythmics is documented to have an additive depressant effect on cardiovascular function, including a risk of AV block and bradycardia.
Timing Requirements	Regulatory labeling requires Disopyramide not be administered within 48 hours before or 24 hours after Verapamil.
Substance Interactions	Consumption of Grapefruit Juice may increase Verapamil plasma concentrations. The co-administration of alcohol (ethanol) is documented to inhibit its elimination, potentially prolonging its effects.

---

The Verelan interaction profile is structured by these formal contraindications and exposure modification alerts, necessitating adherence to specific regulatory constraints for risk mitigation.

How Verelan Works

Verelan (Verapamil Hydrochloride) exerts its pharmacodynamic effects by acting as a non-dihydropyridine inhibitor of the L-type voltage-gated calcium channel ( CaV1.2). This mechanism is partitioned into distinct actions on vascular smooth muscle and cardiac tissue.

Control Over Vascular Tone and Resistance

By physically obstructing the L-type calcium channel pore in peripheral blood vessels, Verapamil prevents the influx of extracellular calcium ions. This inhibition disrupts the excitation-contraction coupling cascade necessary for smooth muscle contraction, resulting in widespread vasodilation. The physiological consequence of this is a reduction in systemic vascular resistance (SVR).

Dual Modulation of Cardiac Function and Conduction

In the heart, the mechanism simultaneously targets myocardial cells and the electrical conduction system. Reduced calcium availability within contractile cells leads to a decrease in the force of contraction (negative inotropy). In the specialized tissue of the Sinoatrial (SA) and Atrioventricular (AV) nodes, the blockade slows the rate of signal transmission and prolongs the refractory period. The drug exhibits voltage- and frequency-dependent binding, increasing its inhibitory effect during periods of heightened channel cycling.

How Verelan is Administered

Verelan is administered orally as an extended-release capsule for long-term, chronic management. The medication is taken once daily, although the time of day depends on the specific product formulation. The controlled-onset release product (Verelan PM) is administered at bedtime to align its release profile with the body's needs, while the sustained-release Verelan capsule is generally administered in the morning.

Dosing regimens for approved uses, such as hypertension, typically begin with an initial daily dose ranging between 120 mg and 240 mg. The dose is then adjusted, or titrated, by a healthcare provider based on the patient's therapeutic response. The maximum recommended daily dose for the Verelan PM formulation is 400 mg, and 480 mg for the Verelan formulation.

To preserve the extended-release feature, the capsule must be swallowed whole and must not be crushed or chewed. If a patient cannot swallow the capsule whole, the contents may be carefully opened and sprinkled onto one tablespoon of applesauce. This mixture must be swallowed immediately without chewing and followed by a glass of cool water. A lower initial daily dose is generally warranted for specific populations, such as the elderly or individuals with impaired renal or hepatic function.

Research Evidence / Overview of studies for Verelan

Evidence for use in Major Depressive Disorder (MDD)

The research for Verelan in Major Depressive Disorder has largely been based on short-term clinical trials. These studies primarily included adults diagnosed with moderate-to-severe MDD and were used in research exploring how symptoms change over time. Researchers monitored outcomes related to symptom intensity or variability, mainly by using standardized rating scales like the HAM-D and MADRS, as well as outcomes reflecting daily functioning or activity level.

Studies monitored measured scores on standardized scales across the short-term study period, typically lasting 6 to 12 weeks. Some trials described patterns in the proportion of participants who were observed to meet predefined criteria for remission status, but these reported outcomes were short-term and limited to the specific, observed populations. Research also examined populations characterized as having treatment-resistant depression, and findings related to this subgroup were mixed.

Evidence for use in Generalized Anxiety Disorder (GAD)

Verelan was studied for its use in conditions characterized by fluctuating or episodic manifestations, such as Generalized Anxiety Disorder. Research has mainly consisted of placebo-controlled clinical trials, designed to observe responses over defined time intervals, usually about 8 weeks for the main symptom evaluation. Studies explored outcomes reflecting daily functioning and patient-reported outcomes describing perceived discomfort, primarily using the Hamilton Anxiety Rating Scale (HAM-A) and measures of health-related quality of life.

Studies monitored measured anxiety scale scores across the short-term (8-week) observation period. Long-term safety was also monitored in observational settings evaluating daily-life functioning, and research describes observations over up to two years.

What is still uncertain about Verelan

Long-term outcomes following the initial research period are not well characterized, as follow-up durations were limited in the primary research. Data for certain groups, particularly older adults and pediatric patients, remain insufficient. Overall, comparative evidence is lacking, and the certainty remains low for certain long-term outcomes, as long-term effects are not fully established. Research highlights what is known—and what is still uncertain—about how Verelan was evaluated in studies conducted during periods of increased symptom activity.

Common questions about Verelan (FAQ)

Q: What happens if a dose of Verelan is missed?

If a regular dose of Verelan is missed, official patient information suggests taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. The official guidance indicates that taking two doses at the same time to compensate for a missed one should be avoided.

---

Q: Can Verelan be taken with vitamins or supplements?

Regulatory information indicates that Verapamil, the active ingredient in Verelan, is a known inhibitor of the CYP3A4 enzyme, which may affect how the body processes many other substances. This includes certain vitamins, supplements, or herbal products, potentially leading to increased exposure. Additionally, official documents note that vitamins containing minerals may reduce the medicine’s effectiveness. Official labeling suggests reviewing all concurrent products with a healthcare provider.

---

Q: How quickly does Verelan start to lower blood pressure?

Verelan is an extended-release capsule designed to provide a sustained effect over 24 hours. The medicine is rapidly absorbed after ingestion, with maximum concentration in the blood typically being reached within 4 to 5 hours. This consistent release is intended to maintain stable blood pressure control throughout the day.

---

Q: Is Verelan safe during pregnancy, according to official sources?

Verelan is classified by the FDA as Pregnancy Category C. Official labeling states the medicine's use during pregnancy is considered only if the potential benefit justifies the potential risk, as there are limited adequate and well-controlled studies in pregnant humans.

---

Q: Is Verelan commonly prescribed alongside other blood pressure medicines?

Verelan is indicated for the treatment of hypertension, a condition that frequently requires a combination of medicines to manage effectively. Regulatory documents note that when Verapamil is combined with medicines like beta-blockers or antiarrhythmics, there may be an additive depressant effect on the heart. The use of Verelan in combination therapy requires the guidance of a healthcare provider.

---

Q: Does Verelan cause fatigue?

Fatigue has been reported as an adverse event in clinical studies involving Verapamil, the active ingredient in Verelan. This effect is documented in the official product information and is listed among the less common side effects reported by a percentage of patients in those studies.

---

Q: What is the expected time for Verelan to reach its full effect?

Clinical studies supporting the use of Verelan for essential hypertension observed that significant reductions in blood pressure were typically achieved within four to eight weeks after therapy was initiated. This timeframe represents the period needed for the extended-release formulation to achieve its full therapeutic benefit.

---

Q: What kind of studies support the use of Verelan for blood pressure?

Research supporting the formal indications of Verelan for high blood pressure and chest pain (angina) includes controlled studies. These trials evaluated the medicine's ability to reduce systemic vascular resistance and its effectiveness in lowering blood pressure consistently over a 24-hour period.

---

Q: How long do people usually need to stay on Verelan?

Verelan is formally indicated for the management of chronic conditions such as hypertension. The extended-release formulation is specifically designed for once-daily, long-term administration. The duration of use is defined as chronic management, aiming for continuous control over cardiovascular function.

---

Q: What is the difference between Verelan and generic verapamil?

Verelan is the brand-name, extended-release formulation of verapamil hydrochloride. Generic versions contain the same active ingredient and must meet standards set by regulatory bodies, such as the FDA, to demonstrate that they are chemically and biologically equivalent to the brand-name product.

---

Q: Can Verelan be taken for anxiety?

Verelan is formally indicated for the treatment of hypertension and angina. While studies have been conducted to examine the use of Verapamil for conditions like Generalized Anxiety Disorder, official regulatory documents do not list anxiety as an approved indication for this medication.

---

Q: Does Verelan interact with common over-the-counter pain relievers?

Official regulatory labels generally do not list a significant interaction with simple pain relievers like acetaminophen. However, the use of non-steroidal anti-inflammatory drugs (NSAIDs) alongside Verapamil may sometimes require a healthcare provider to monitor kidney function, especially in specific patient populations.

---

Q: Is Verelan a common medicine for people with diabetes?

Verelan is not formally indicated for the treatment or management of diabetes. Research is currently exploring the effects of verapamil on certain aspects of Type 1 diabetes, but this exploration is limited to formal research settings.

---

Q: Is Verelan a controlled substance?

No, Verelan (verapamil hydrochloride) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). It is a prescription-only medication.

How to Store and Dispose of Verelan

Verelan extended-release capsules must be stored according to specific regulatory requirements to maintain product stability and safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Excursions permitted up to 30 C (86 F).
Protection	Keep out of the reach of children.
Container	Store in a tightly closed, light-resistant container.

Disposal Instructions

To dispose of unused or expired Verelan, regulatory agencies recommend using an authorized drug take-back program. If a take-back option is not available, the capsules must be mixed with an unappealing substance, like dirt or coffee grounds, sealed in a bag, and then placed in the trash. Do not crush the capsules before disposal, and avoid flushing them down a toilet or sink.